Skip to main content
SpringerLink
Log in

VTE risk included in the new safety information about Evra

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Janssen-Ortho Inc.EVRA (norelgestromin and ethinyl estradiol) transdermal system. Company Communication: [3 pages], 21 Nov 2006. Available from: URL: http://www.hc-sc.gc.ca

  2. Health Canada.New safety information about EVRA* (norelgestromin and ethinyl estradiol) Transdermal System. Media Release: 21 Nov 2006. Available from: URL: http://www.hc-sc.gc.ca

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

VTE risk included in the new safety information about Evra. React. Wkly. 1130, 2 (2006). https://doi.org/10.2165/00128415-200611300-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200611300-00002

Keywords

Search

Navigation